Selecting for BRCA1 testing using a combination of homogeneous selection criteria and immunohistochemical characteristics of breast cancers

GianMaria Miolo, Vincenzo Canzonieri, Clelia De Giacomi, Lara D. Puppa, Riccardo Dolcetti, Davide Lombardi, Tiziana Perin, Simona Scalone, Andrea Veronesi, Alessandra Viel

Research output: Contribution to journalArticlepeer-review

Abstract

Background: BRCA1 gene-related tumours are more frequently estrogen receptor (ER) and progesterone receptor (PR) negative with a lower prevalence of human epidermal growth factor receptor 2 (HER2) overexpression or amplification. We evaluated the effectiveness of a combination of homogeneously selected criteria and immunohistochemical (IHC) characteristics of Familial Breast Cancers (FBCs) in detecting BRCA1 mutation carriers. Methods: Primary breast tumours from 93 FBC patients defined by specific eligibility criteria, based on personal and familial tumour history, were evaluated by Allred's method. The BRCA1 molecular analysis, including Multiplex Ligation-dependent Probe Amplification (MLPA), was considered as the gold standard assay. Results: A total of 10 BRCA1 pathogenetic mutations was found. With the exclusion of the tumours characterized by double positive receptorial status and/or strong HER2 positivity (3+), we identified 22 patients, 10 of whom resulted as BRCA1 mutation carriers. The sensitivity, specificity, positive and negative predictive values were 100%, 83.3%, 45.4% and 100% respectively. Conclusion: Our findings suggest that the IHC analysis by Allred's method improves our ability to select patients for BRCA1 testing.

Original languageEnglish
Article number1471
Pages (from-to)360
Number of pages1
JournalBMC Cancer
Volume9
DOIs
Publication statusPublished - Oct 10 2009

ASJC Scopus subject areas

  • Cancer Research
  • Genetics
  • Oncology

Fingerprint Dive into the research topics of 'Selecting for BRCA1 testing using a combination of homogeneous selection criteria and immunohistochemical characteristics of breast cancers'. Together they form a unique fingerprint.

Cite this